704208-25-3

Usage

Uses

Used in Medicinal Chemistry:
7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with improved binding affinity and selectivity towards biological targets, contributing to the advancement of novel therapeutic agents.
Used in Drug Development:
In the realm of drug development, 7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE serves as a valuable building block for the creation of innovative medications. Its structural attributes may enhance the potency, efficacy, and safety profiles of new drugs, offering potential solutions to unmet medical needs.
Used in Organic Synthesis:
7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE is employed as a versatile starting material in organic synthesis, enabling the preparation of a wide range of chemical compounds. Its reactivity and functional group compatibility make it suitable for the synthesis of various organic molecules, including pharmaceuticals and agrochemicals.
Used in Agrochemicals:
7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE is also used as a precursor in the development of agrochemicals, such as pesticides and herbicides. Its structural features may contribute to the design of more effective and environmentally friendly agrochemicals, addressing challenges in modern agriculture.

InChI:InChI=1/C10H10F3NO/c11-10(12,13)6-1-2-7-8(14)3-4-15-9(7)5-6/h1-2,5,8H,3-4,14H2

Upstream product

• 890838-99-0 7-trifluoromethyl-chroman-4-one O-methyl-oxime 
• 111141-02-7 2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-one 

Downstream Products

• 1140496-05-4 (S)-7-(trifluoromethyl)chroman-4-amine 

Relevant academic research and scientific papers

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES and INFLAMMATION

Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.